Facebook Advertising
for Mass Torts

Why Facebook Dominates Mass Tort Advertising

Facebook and Instagram, operated by Meta, account for the largest share of mass tort advertising spend in the United States. The platform's dominance in this category is driven by three structural advantages: the age skew of its user base aligns with mass tort claimant demographics; its targeting infrastructure allows precise audience construction; and its scale provides access to the hundreds of millions of potential claimants that major pharmaceutical and product liability torts require.

MTAA has managed Facebook mass tort campaigns continuously since 2013 — before any competitor recognized the channel's potential. At peak periods, MTAA has managed $3–4 million in monthly Meta advertising spend across active tort campaigns. This scale produces the data that informs everything in this guide.

The Andromeda Engine — What Changed in 2025

Meta's core ad delivery system is now the Andromeda engine — an AI-powered ad retrieval system built on NVIDIA GH200 infrastructure. Global rollout completed October 2025. Andromeda fundamentally changes how mass tort campaigns should be structured.

• 100x faster at matching people to ads across the full Meta inventory
• 10,000x more ad variants processed in parallel — the algorithm reads your creative and finds who resonates with it
• Creative is now the targeting. Andromeda shifts Meta from audience-first to creative-first. The algorithm reads your ad copy and imagery, identifies the population that matches, and delivers there — regardless of your targeting settings
• Legacy over-segmented structures saw 20–35% worse ROAS post-Andromeda. Too many ad sets, too few creatives, too narrow audiences — all punished

Post-Andromeda Campaign Structure

• 1–3 ad sets per campaign maximum (not 5–10)
• 10–20 unique creatives per ad set (not 3–5) — volume feeds the algorithm
• One objective per campaign — clean signal, no mixed-goal campaigns
• Campaign Budget Optimization (CBO) at campaign level
• Broad or Advantage+ Audience — let Andromeda expand; over-restriction starves it
• Learning phase needs 50 conversions per week — do not reset with unnecessary edits
• Minimum 3–5 days before evaluating performance — early kills destroy data

Targeting Architecture for Mass Torts

Effective mass tort targeting on Facebook combines three audience construction approaches, layered in sequence:

• Interest and Health-Based Targeting — Users who have expressed interest in specific medical conditions, medications, or health topics relevant to the tort. Facebook's health and wellness interest categories, combined with pharmaceutical brand interests, allow initial audience construction without first-party data. This is the cold audience layer.
• Demographic Layering — Age, gender, and geographic filters applied on top of interest targeting to match the eligible claimant profile. Pharmaceutical torts often require specific age windows; environmental torts require geographic precision (proximity to contamination sites, military base water systems, industrial corridors).
• Lookalike Audiences — Audiences built from existing signed claimant lists. Upload 1,000+ signed retainers and Facebook identifies users with similar behavioral and demographic profiles. Consistently the highest-performing audience type in mature tort campaigns. This is why intake quality directly affects advertising performance.

The Algorithm Does the Targeting — The Copy Opens the Door

Under Andromeda, the opening line of ad copy does more targeting work than most demographic settings. Call out exactly who you're looking for at the very start:

• "Parents of children ages 9–17 who use social media..."
• "Women with a transvaginal mesh implant who experienced complications..."
• "People diagnosed with non-Hodgkin's lymphoma who used Roundup..."

This self-selection mechanism tells the right person the ad is for them. They engage. Andromeda learns from those engagements. The audience self-refines. Do not overthink demographic targeting when the copy can do this work more efficiently.

Creative Strategy — What Works for Claimant Acquisition

The proven mass tort ad structure: Headline = Problem Statement. CTA = Solution. Lead with the condition, not the answer. "Diagnosed with lung cancer after AFFF exposure?" stops the scroll for the right person. "Free Case Review — See If You Qualify" is the low-friction first step.

Two emotional registers drive mass tort performance:

Leave everything running. What looks like a low-performer at day 3 may be the strongest converter at day 14 for a specific sub-segment. Andromeda routes creative to the right sub-audience automatically. Stopping ads early kills conversion data and starves the algorithm. Do not pick a single winner and kill the rest.

The Pixel Architecture — How MTAA Structures Data

MTAA runs multiple torts inside the same Meta ad account. Separation happens at the pixel level — not the account level. Each tort gets its own dedicated pixel:

• Social Media Addiction pixel
• Roundup / Glyphosate pixel
• AFFF Firefighting Foam pixel
• (one per active tort)

Algorithm learning for one tort does not bleed into another. Signals stay clean and tort-specific. One ad account, one billing relationship, one account health profile — fully isolated performance data per tort.

The Three-Event Funnel

• Page View — fires on landing page load. Top of funnel signal. Tells Meta this URL was visited.
• Lead — fires when the claimant completes qualification inside the CloudIntake iframe. Qualified interest confirmed.
• Purchase (Signed Retainer) — fires when the claimant signs the retainer. This is the optimization event. This is the signal that trains Andromeda to find more people like this person.

Most campaigns optimize on Lead. MTAA optimizes on Purchase. Optimizing on Lead trains the algorithm to find form-fillers — which may include unqualified claimants. Optimizing on Purchase trains it to find signers. The signed retainer feedback loop is the most important structural advantage in MTAA's campaign architecture.

The Conversions API (CAPI) and HIPAA

Meta's Conversions API (CAPI) has been essential infrastructure since 2021. CAPI sends conversion events directly from the server to Meta — bypassing iOS privacy restrictions and browser-side tracking limitations that have degraded pixel-only measurement.

For mass tort campaigns, CAPI implementation requires careful HIPAA consideration. When intake forms collect medical information (drug names, diagnosis details, injury descriptions), that data becomes Protected Health Information (PHI) under HIPAA. PHI cannot be transmitted to Meta through CAPI without proper Business Associate Agreement structures and data de-identification protocols.

MTAA's CAPI implementation uses a hashed, de-identified event structure — conversion signals pass without PHI transmission, maintaining HIPAA compliance while preserving full optimization capability.

Navigating Meta's Health and Legal Restrictions

Meta imposed Health & Wellness Special Category restrictions in January 2025, affecting any business associated with medical conditions, health statuses, or provider-patient relationships. Key restrictions for mass tort campaigns:

• No lower-funnel event optimization in health-adjacent campaigns — use Lead, Landing Page View, or Content Interaction events as the optimization objective
• Limited custom and lookalike audience construction using health-related data
• No sensitive attribute targeting in copy (cannot directly reference a person's health status)
• Guarantee language ("Win your case," "You will recover") triggers automatic rejection
• Shocking or graphic injury imagery triggers policy enforcement
• Repeated violations escalate to ad account restriction or permanent disabling

Mass tort content has historically not been a major enforcement problem — the only consistent enforcement area is body image content. The standard practice: no guarantee language, copy invites self-identification ("If you've been diagnosed with X") rather than asserting the reader has a condition. Informational framing — presenting the litigation as news — consistently outperforms direct solicitation while also avoiding policy flags.

Cost Benchmarks